Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

被引:27
|
作者
Khan, O. A. [1 ]
Blann, A. D. [2 ]
Payne, M. J. [1 ]
Middleton, M. R. [1 ]
Protheroe, A. S. [1 ]
Talbot, D. C. [1 ]
Taylor, M. [1 ]
Han, C. [1 ]
Patil, M. [1 ]
Harris, A. L. [1 ]
机构
[1] Univ Oxford, Dept Med Oncol, Churchill Hosp, Oxford OX3 7LJ, England
[2] City Hosp, Univ Dept Med, Birmingham B18 7QH, W Midlands, England
关键词
celecoxib; low-dose chemotherapy; angiogenesis; METASTATIC BREAST-CANCER; II CLINICAL-TRIAL; ORAL CYCLOPHOSPHAMIDE; PHASE-II; CYCLOOXYGENASE-2; INHIBITORS; METRONOMIC CHEMOTHERAPY; ANTITUMOR-ACTIVITY; VINBLASTINE; EXPRESSION; THERAPY;
D O I
10.1038/bjc.2011.154
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Combined therapy of metronomic cyclophosphamide, methotrexate and high-dose celecoxib targeting angiogenesis was used in a phase II trial. METHODS: Patients with advanced cancer received oral cyclophosphamide 50 mg o.d., celecoxib 400 mg b.d. and methotrexate 2.5 mg b.d. for two consecutive days each week. Response was determined every 8 weeks; toxicity was evaluated according to CTC version 2.0. Plasma markers of inflammation, coagulation and angiogenesis were measured. RESULTS: Sixty-seven of 69 patients were evaluable for response. Twenty-three patients had stable disease (SD) after 8 weeks, but there were no objective responses to therapy. Median time to progression was 57 days. There was a low incidence of toxicities. Among plasma markers, levels of tissue factor were higher in the SD group of patients at baseline, and levels of both angiopoietin-1 and matrix metalloproteinase-9 increased in the progressive disease group only. There were no changes in other plasma markers. CONCLUSION: This metronomic approach has negligible activity in advanced cancer albeit with minimal toxicity. Analysis of plasma markers indicates minimal effects on endothelium in this trial. These data for this particular regimen do not support basic tenets of metronomic chemotherapy, such as the ability to overcome resistant tumours by targeting the endothelium. British Journal of Cancer (2011) 104, 1822-1827. doi: 10.1038/bjc.2011.154 www.bjcancer.com Published online 17 May 2011 (C) 2011 Cancer Research UK
引用
收藏
页码:1822 / 1827
页数:6
相关论文
共 50 条
  • [1] Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
    O A Khan
    A D Blann
    M J Payne
    M R Middleton
    A S Protheroe
    D C Talbot
    M Taylor
    C Han
    M Patil
    A L Harris
    British Journal of Cancer, 2011, 104 : 1822 - 1827
  • [2] Erratum: Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
    O A Khan
    A D Blann
    M J Payne
    M R Middleton
    A S Protheroe
    D C Talbot
    M Taylor
    O Kirichek
    C Han
    M Patil
    A L Harris
    British Journal of Cancer, 2011, 105 : 1252 - 1252
  • [3] Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (vol 104, pg 1822, 2011)
    Khan, O. A.
    Blann, A. D.
    Payne, M. J.
    Middleton, M. R.
    Protheroe, A. S.
    Talbot, D. C.
    Taylor, M.
    Kirichek, O.
    Han, C.
    Patil, M.
    Harris, A. L.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1252 - 1252
  • [4] Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer
    Scheusan, R.
    Curescu, S.
    Stanculeanu, D.
    Curescu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] LOW-DOSE METRONOMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND METHOTREXATE IN METASTATIC BREAST CANCER PATIENTS
    Krajnak, S.
    Battista, M.
    Elger, T.
    Stewen, K.
    Heimes, A. S.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 116 - 116
  • [6] LOW-DOSE METRONOMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND METHOTREXATE IN METASTATIC BREAST CANCER PATIENTS
    Krajnak, S.
    Battista, M.
    Elger, T.
    Stewen, K.
    Heimes, A. S.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 636 - 636
  • [7] Phase II study of 'high-dose' celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
    Abdel-Bary, N.
    Hashem, T.
    Metwali, H.
    Abd el Ghany, A.
    Magied, H. A.
    El-Herbeiny, M.
    ECANCERMEDICALSCIENCE, 2009, 3
  • [8] A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
    Monika K. Krzyzanowska
    Ian F. Tannock
    Gina Lockwood
    Jennifer Knox
    Malcolm Moore
    Georg A. Bjarnason
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 135 - 141
  • [9] A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
    Krzyzanowska, Monika K.
    Tannock, Ian F.
    Lockwood, Gina
    Knox, Jennifer
    Moore, Malcolm
    Bjarnason, Georg A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 135 - 141
  • [10] CONTINUOUS LOW-DOSE CYCLOPHOSPHAMIDE (NSC-26271) THERAPY IN ADVANCED OVARIAN CANCER
    MANGIONI, C
    BOLIS, G
    NATALE, N
    MORASCA, L
    EUROPEAN JOURNAL OF CANCER, 1976, 12 (05) : 353 - 356